Correction to: Scientific Reports https://doi.org/10.1038/s41598-020–79918-3, published online 08 January 2021.
This Article contains errors.
In the Introduction,
“Among them, the structural proteins, membrane (M), envelope (E), nucleocapsid (N), hemagglutinin-esterase (HE) and spike (S) proteins contribute notably in viral transmission and replication in the host cells7.”
should read:
“Among them, the structural proteins, membrane (M), envelope (E), nucleocapsid (N) and spike (S) proteins contribute notably in viral transmission and replication in the host cells7.”
Additionally, Reference 7 is incorrectly given as:
Shanmugaraj, B., Siriwattananon, K., Wangkanont, K. & Phoolcharoen, W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac. J. Allergy Immunol. 38, 10–18 (2020).
The correct reference is listed below:
Sharma, A., Tiwari, V. & Sowdhamini, R. Computational search for potential COVID-19 drugs from FDA-approved drugs and small molecules of natural origin identifies several anti-virals and plant products. J Biosci 45, 100 (2020). https://doi.org/10.1007/s12038-020-00069-8.
These changes do not affect the conclusions of the Article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Fakhar, Z., Khan, S., AlOmar, S.Y. et al. Author Correction: ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19. Sci Rep 14, 24370 (2024). https://doi.org/10.1038/s41598-024-76253-9
Published:
Version of record:
DOI: https://doi.org/10.1038/s41598-024-76253-9
